Further studies on the blockade of spinal CASP6 under painful pathophysiologic conditions such as bone cancer pain, sickle cell disease, or inflammatory bowel disease may represent another important therapeutic opportunity in analgesic development. Here, CASP6 is linked to bone cancer.